Clinical trials: Respiratory Therapy
Non Small Cell Lung Cancer
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
- Trial name
- FORTIS-M (NCT00707304)
- Testing
- Talactoferrin
- Where
- 189 sites in United States, Australia and 21 more
- Volunteers
- 742 people
- Sponsor
- Agennix
Carcinoma, Non-Small-Cell Lung
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune responses against proteins…
- Trial name
- NCT01909752
- Testing
- Cyclophosphamide, DRibble vaccine, Imiquimod
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- UbiVac
COVID-19
Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy
The study is designed as a multicenter, randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of tofacitinib in hospitalized adult participants with COVID-19 pneumonia who are receiving SoC…
- Trial name
- NCT04412252
- Testing
- Tofacitinib
- Where
- 6 sites in United States
- Sponsor
- Pfizer
Viral Respiratory Tract Infection
Safety and Tolerability of Single and Multiple Doses of Neumifil
This is a Phase 1, single-centre, randomised, placebo-controlled first in human study in healthy subjects. The study will assess the safety and tolerability of single-ascending (Part A) and multiple-ascending (Part B) doses of…
- Trial name
- NCT05093530
- Testing
- Neumifil
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pneumagen Ltd.
COVID-19
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.
- Trial name
- NCT06004128
- Testing
- VYD222
- Sponsor
- Invivyd, Inc.
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Non-small-cell Lung Cancer
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
The purpose of this study is to evaluate the overall response rate and disease free survival for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.
- Trial name
- NCT01843647
- Testing
- Icotinib, Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Asthma, Severe Eosinophilic Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe…
- Trial name
- NCT04159519
- Testing
- Symbicort®, Fasenra®, Ventolin®
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NEXUS (NCT00449033)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Gemcitabine, Cisplatin
- Where
- 122 sites in Austria, Belgium and 16 more
- Volunteers
- 904 people
- Sponsor
- Bayer
Rhinitis, Allergic
Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)
The purpose of this study is to evaluate the safety and efficacy of mometasone furoate nasal spray (MFNS) with the addition of loratadine vs MFNS alone, loratadine alone, or placebo, in the treatment of patients with seasonal…
- Trial name
- NCT03855228
- Testing
- Mometasone furoate nasal spray (MFNS), Loratadine
- Volunteers
- 704 people
- Sponsor
- Organon and Co
Pneumonia
Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia
The purpose of this study is to compare the clinical cure rate (ratio of clinically cured patients to the total number of patients) of ceftobiprole medocaril versus a comparator in the treatment of patients with…
- Trial name
- NCT00326287
- Testing
- Ceftobiprole medocaril, Ceftriaxone with or without Linezolid
- Volunteers
- 638 people
- Sponsor
- Basilea Pharmaceutica
Pulmonary Arterial Hypertension
Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)
This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study.
- Trial name
- NCT00993408
- Testing
- ACT-293987 (NS-304)
- Where
- 8 sites in Austria, Belgium and 6 more
- Volunteers
- 43 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III.
- Trial name
- NCT05934526
- Testing
- Seralutinib, Generic Dry Powder Inhaler
- Where
- 166 sites in United States, Argentina and 29 more
- Volunteers
- 390 people
- Sponsor
- GB002, Inc.
Chronic Obstructive Pulmonary Disease
A Study to Assess the Long-term Safety of QVA149
The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- ENLIGHTEN (NCT01120717)
- Testing
- QVA149
- Where
- 53 sites in Canada, France and 8 more
- Volunteers
- 339 people
- Sponsor
- Novartis Pharmaceuticals
Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell…
- Trial name
- NCT06736418
- Testing
- 225Ac-ABD147
- Where
- 12 sites in United States
- Volunteers
- 17 people
- Sponsor
- Abdera Therapeutics Inc.
Melanoma, Non Small Cell Lung Cancer
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
- Trial name
- NCT05366478
- Testing
- Autologous tumor infiltrating lymphocytes (TILs)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting.
- Trial name
- NCT03456076
- Testing
- Alectnib, Cisplatin, Vinorelbine
- Where
- 114 sites in United States, Australia and 25 more
- Volunteers
- 257 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Carcinoma
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
This is the first study where BAY1000394 is given in combination with chemotherapy: cisplatin / etoposide or carboplatin / etoposide. Patients with small cell lung cancer will be treated.
- Trial name
- NCT01573338
- Testing
- Roniciclib (BAY1000394), Etoposide, Cisplatin
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 43 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
A single arm, open label, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR.
- Trial name
- NCT01646450
- Testing
- Icotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
SARS-CoV-2 Infection
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
- Trial name
- PROTECT (NCT04834908)
- Testing
- Equine COVID-19 Antiserum, Standard of care
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Bharat Serums and Vaccines Limited